Year All2024202320222021 Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023 08-02-2023 Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference 07-19-2023 Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023 06-20-2023 Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest 06-13-2023 Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023 06-03-2023 Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results 05-15-2023 Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023 05-10-2023 Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023 05-09-2023 Zevra Announces Board of Directors and Leadership Changes 05-08-2023 Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy 05-03-2023
Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023 06-20-2023
Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest 06-13-2023
Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023 06-03-2023
Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023 05-10-2023